Figure 8From: Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibitionSalirasib inhibits tumour growth in a subcutaneous xenograft model. HepG2 cells were injected subcutaneously in the lower right flank of female NMRI nude mice. When palpable tumors were established, mice were treated with 10 mg/kg/day i.p. salirasib or vehicle for 12 days. A. Tumour volume was assessed three times per week as described in 'Materials and Methods'. Data are presented as mean ± SEM. B. At the end of the treatment period, animals were sacrificed and tumour weights were recorded. Boxplot of mean tumor volume at the time of sacrifice. C. Photographs of the smallest and largest tumours in the control group (CTL) and the FTS group (salirasib). * P < 0.05 ** P < 0.01 in treated group (n = 6) versus control group (n = 4).Back to article page